Allakos Inc, based in San Carlos, CA, is a biopharmaceutical company dedicated to developing therapeutic antibodies that target immunomodulatory receptors on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Their lead programs focus on inhibiting mast cell and eosinophil activation, as these cells play a pathogenic role in various inflammatory conditions.
With a focus on novel biology, Allakos is conducting Phase 2 studies in Chronic Spontaneous Urticaria and Atopic Dermatitis, utilizing investigational monoclonal antibodies such as Lirentelimab (AK002) to deplete eosinophils and inhibit mast cells, and AK006 to selectively and potently inhibit mast cells, including KIT mediated signaling. Their commitment lies in addressing the needs of patients suffering from chronic inflammatory diseases through innovative therapeutic approaches.
Generated from the website